Kala Bio, INC. (KALA) — 8-K Filings

All 8-K filings from Kala Bio, INC.. Browse 20 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (20)

8-K Filing — Dec 29, 2025
8-K Filing — Dec 16, 2025
KALA BIO, Inc. Files 8-K for Material Agreement — Dec 5, 2025 Risk: medium
KALA BIO, Inc. filed an 8-K on December 5, 2025, reporting on events that occurred on December 4, 2025. The filing indicates the entry into a material definitiv
Kala Bio Announces Material Agreements & Equity Sales — Nov 25, 2025 Risk: medium
Kala Bio, Inc. announced on November 20, 2025, the termination of a material definitive agreement and entered into a new material definitive agreement. The comp
8-K Filing — Nov 12, 2025
KALA BIO, Inc. Reports Material Agreements and Equity Sales — Nov 10, 2025 Risk: medium
KALA BIO, Inc. filed an 8-K on November 10, 2025, reporting on several key events that occurred on November 9, 2025. These include entering into a material defi
Kala Bio, Inc. Files 8-K on Executive Changes and Restructuring — Oct 20, 2025 Risk: medium
Kala Bio, Inc. filed an 8-K on October 20, 2025, reporting on several events. These include cost associated with exit or disposal activities, departure of direc
KALA BIO, Inc. Reports Financial Obligation Triggering Event — Oct 1, 2025 Risk: medium
KALA BIO, Inc. filed an 8-K on October 1, 2025, reporting a triggering event that accelerates or increases a direct financial obligation or an obligation under
KALA BIO, Inc. Files 8-K on Exit Activities — Sep 29, 2025 Risk: medium
KALA BIO, Inc. filed an 8-K on September 29, 2025, reporting on events as of September 28, 2025. The filing indicates costs associated with exit or disposal act
KALA BIO, Inc. Files 8-K on Shareholder Nominations — Sep 18, 2025 Risk: medium
KALA BIO, Inc. filed an 8-K on September 18, 2025, reporting events as of September 16, 2025. The filing pertains to Shareholder Nominations Pursuant to Exchang
KALA BIO, Inc. Files 8-K on Executive Changes and Financials — Sep 2, 2025 Risk: low
KALA BIO, Inc. filed an 8-K on August 29, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certa
KALA BIO, Inc. Files 8-K — Jul 9, 2025 Risk: low
KALA BIO, Inc. filed an 8-K on July 9, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it confirms th
Kala Bio Announces Board and Executive Compensation Changes — Apr 11, 2025 Risk: medium
Kala Bio, Inc. announced on April 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certa
Kala Bio Announces Board and Executive Changes — Feb 12, 2025 Risk: medium
KALA BIO, Inc. announced on February 11, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of ce
Kala Bio Files 8-K: Material Agreement, Equity Sales, Bylaw Changes — Dec 30, 2024 Risk: medium
Kala Bio, Inc. filed an 8-K on December 30, 2024, reporting events as of December 29, 2024. The filing indicates an entry into a material definitive agreement,
Kala Bio Announces CMO Departure, New Directors — Sep 25, 2024 Risk: medium
Kala Bio, Inc. announced on September 23, 2024, the departure of its Chief Medical Officer, Dr. Marcus Magnus, effective September 20, 2024. The company also ap
Kala Bio Announces Material Agreement and Equity Transactions — Jun 27, 2024 Risk: medium
Kala Bio, Inc. announced on June 26, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
KALA BIO Files 8-K on Shareholder Vote Matters — Jun 12, 2024 Risk: low
KALA BIO, Inc. filed an 8-K on June 12, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 11, 2024. The company, fo
KALA BIO, Inc. Files 8-K: Material Agreement & Equity Sales — Mar 26, 2024 Risk: medium
KALA BIO, Inc. announced on March 25, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity secu
Bausch + Lomb to Acquire KALA BIO, Inc. — Mar 4, 2024 Risk: medium
KALA BIO, Inc. announced on March 4, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Bausch + Lomb Corporation. The tran

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX